KR840004756A - 항 정신질환제의 제조방법 - Google Patents

항 정신질환제의 제조방법 Download PDF

Info

Publication number
KR840004756A
KR840004756A KR1019830002255A KR830002255A KR840004756A KR 840004756 A KR840004756 A KR 840004756A KR 1019830002255 A KR1019830002255 A KR 1019830002255A KR 830002255 A KR830002255 A KR 830002255A KR 840004756 A KR840004756 A KR 840004756A
Authority
KR
South Korea
Prior art keywords
formula
compound
carbon atoms
alkyl
reacting
Prior art date
Application number
KR1019830002255A
Other languages
English (en)
Other versions
KR870000931B1 (ko
Inventor
에이. 디월드 호레이스
Original Assignee
제리 에이. 바이스바크
워니-램버트 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제리 에이. 바이스바크, 워니-램버트 컴페니 filed Critical 제리 에이. 바이스바크
Publication of KR840004756A publication Critical patent/KR840004756A/ko
Application granted granted Critical
Publication of KR870000931B1 publication Critical patent/KR870000931B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

항 정신질환제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 일반식(5)의 화합물을 요오드화물 및 아지드화물로부터 선택한 음이온과 반응시켜 일반식(la)의 화합물을 제조하는 방법.
    식중, R1, R2, R3, R4및 R5는 H, 탄소원자 1내지 6개와 알킬기 또는 탄소원자 1내지 3개의 불화알킬 ; R4는 H/H일 수 있으며 R5는 각 알킬기가 탄소원자 1내지 6개인 디알킬이거나, R5는 H/H일수 있으며 R4는 각 알킬기가 탄소원자 1내지 6개인 디알킬 일 수 있다.
  2. 일반식(8)의 화합물을 일반식 R3C(OR)3의 오르토에스테르와 반응시켜 제1항에 나타낸 일반식(1a)의 화합물을 제조하는 방법.
    식중, R1, R2, R3, R4및 R5는 제1항에서와 같으며, R은 탄소원자 1내지 6개의 알킬이다.
  3. 일반식(6)의 화합물을 무기 할로겐화제와 반응시켜 제1항에 나타낸 일반식 (1a)의 화합물을 제조하는 방법.
    식중, R1, R2, R3, R4및 R5는 제1항에서와 같다.
  4. 일반식(6)의 화합물을 산과 반응시켜 일반식(1b)의 화합물을 제조하는 방법.
    식중, R1, R2, R3, R4및 R5는 H, 탄소원자 1내지 6개와 알킬 또는 탄소원자 1내지 3개의 불화 알킬이다.
  5. 제1항에 나타낸 일반식(1a)의 화합물을 산화시켜서 제4항에 나타낸 일반식( 1b)의 화합물을 제조하는 방법.
  6. 제2항에 나타낸 일반식(8)의 화합물을 일반식 R3CHO의 알데히드와 반응시켜 일반식(1c)의 화합물을 제조하는 방법.
    식중, R1, R2, R3, R4및 R5는 H, 탄소원자 1내지 6개의 알킬 또는 탄소원자 1내지 3개의 불화알킬이며 ; R4는 H/H일 수 있으며 R5는 각 알킬이 탄소원자 1내지 6개인 디알킬기이거나, R5는 H/H일수 있으며 R4는 각 알킬이 탄소원자 1내지 6개인 디알킬 일 수 있다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830002255A 1982-05-24 1983-05-23 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법 KR870000931B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US381,484 1982-05-24
US381484 1982-05-24
US06/381,484 US4469868A (en) 1982-05-24 1982-05-24 Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

Publications (2)

Publication Number Publication Date
KR840004756A true KR840004756A (ko) 1984-10-24
KR870000931B1 KR870000931B1 (ko) 1987-05-11

Family

ID=23505215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002255A KR870000931B1 (ko) 1982-05-24 1983-05-23 이미다조[1,2-c]-피라졸로[3,4-e]피리미딘의 제조방법

Country Status (22)

Country Link
US (1) US4469868A (ko)
EP (1) EP0095289B1 (ko)
JP (1) JPS58210087A (ko)
KR (1) KR870000931B1 (ko)
AR (1) AR240941A1 (ko)
AT (1) ATE24510T1 (ko)
AU (1) AU553708B2 (ko)
CA (1) CA1210393A (ko)
DE (1) DE3368635D1 (ko)
DK (1) DK161968C (ko)
ES (4) ES522617A0 (ko)
FI (1) FI74012C (ko)
GR (1) GR79262B (ko)
HK (1) HK102989A (ko)
HU (1) HU187913B (ko)
IE (1) IE55111B1 (ko)
IL (1) IL68360A (ko)
NO (1) NO160444C (ko)
NZ (1) NZ204321A (ko)
PH (1) PH18454A (ko)
PT (1) PT76745B (ko)
ZA (1) ZA832637B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000192A1 (en) * 1986-06-26 1988-01-14 Warner-Lambert Company 5-SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDIN-7-ONES
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
CN102238872A (zh) 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9802937B2 (en) * 2011-04-21 2017-10-31 Origenis Gmbh Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422807A (de) * 1963-08-16 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung von Imidazo- und Pyrimidochinazolinen
US3313815A (en) * 1964-05-04 1967-04-11 Sterling Drug Inc 8-chloropyrazolo-[1, 5-c]quinazoline derivatives and methods of preparing same
US3309369A (en) * 1966-04-11 1967-03-14 Wander Ag Dr A Imidazo- and pyrimido-quinazolines
US3594379A (en) * 1968-09-16 1971-07-20 Sandoz Ag 2,3-dihydroimidazo(1,2-c)quinazolines
DE2058501A1 (de) * 1970-11-27 1972-05-31 Bayer Ag Verfahren zur Herstellung von neuen N-verbrueckten bicyclischen Heteroaromaten
GB1347493A (en) * 1971-02-11 1974-02-27 Aspro Nicholas Ltd Benzazine derivatives
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
JPS516993A (en) * 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
JPS5398997A (en) * 1977-02-09 1978-08-29 Sumitomo Chem Co Ltd Fused pyridine derivertives and process for their preparation
US4206123A (en) * 1977-10-31 1980-06-03 Mccall John M Isothiochroman
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
US4250181A (en) * 1977-10-31 1981-02-10 The Upjohn Company Methods of treating psychosis
US4192803A (en) * 1978-09-15 1980-03-11 American Cyanamid Company 5H-Pyrrolo[2,1-c][1,4]benzodiazepine derivatives
GR69858B (ko) * 1978-11-01 1982-07-19 Wellcome Found
CH643263A5 (de) * 1979-05-11 1984-05-30 Sandoz Ag Benzodiazepine, ihre herstellung und verwendung.
HU178523B (en) * 1979-05-18 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing new pyrazolo-quinazoline derivatives
US4230707A (en) * 1979-08-27 1980-10-28 Warner-Lambert Company Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their production
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4409230A (en) * 1982-04-09 1983-10-11 Hoechst-Roussel Pharmaceuticals Inc. Pharmaceutical compositions and methods employing 8-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro-[4.]decan-4-one and derivatives thereof
US4390544A (en) * 1982-04-09 1983-06-28 Hoechst-Roussel Pharmaceuticals Inc. {1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-oxo-1-benzimidazolinyl}p
US4415581A (en) * 1982-04-09 1983-11-15 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines to treat psychoses
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
IE55111B1 (en) 1990-06-06
HU187913B (en) 1986-03-28
PT76745B (en) 1986-04-21
PH18454A (en) 1985-07-18
DK161968B (da) 1991-09-02
DK161968C (da) 1992-02-03
EP0095289B1 (en) 1986-12-30
CA1210393A (en) 1986-08-26
JPH0320395B2 (ko) 1991-03-19
FI831742L (fi) 1983-11-25
NO831792L (no) 1983-11-25
JPS58210087A (ja) 1983-12-07
ES8506004A1 (es) 1985-06-16
AR240941A1 (es) 1991-03-27
NZ204321A (en) 1986-06-11
ZA832637B (en) 1984-01-25
IL68360A0 (en) 1986-10-31
ES8506315A1 (es) 1985-07-01
PT76745A (en) 1983-06-01
NO160444C (no) 1989-04-19
ES529372A0 (es) 1985-06-16
ATE24510T1 (de) 1987-01-15
EP0095289A3 (en) 1984-09-05
FI831742A0 (fi) 1983-05-18
KR870000931B1 (ko) 1987-05-11
ES8506019A1 (es) 1985-06-16
IL68360A (en) 1986-10-31
AU1342783A (en) 1983-12-01
GR79262B (ko) 1984-10-22
US4469868A (en) 1984-09-04
DE3368635D1 (en) 1987-02-05
ES529371A0 (es) 1985-07-01
EP0095289A2 (en) 1983-11-30
ES8407051A1 (es) 1984-09-01
IE830822L (en) 1983-11-24
AU553708B2 (en) 1986-07-24
FI74012C (fi) 1987-12-10
DK227183A (da) 1983-11-25
AR240941A2 (es) 1991-03-27
ES522617A0 (es) 1984-09-01
HK102989A (en) 1990-01-05
ES529373A0 (es) 1985-06-16
DK227183D0 (da) 1983-05-20
FI74012B (fi) 1987-08-31
NO160444B (no) 1989-01-09

Similar Documents

Publication Publication Date Title
KR840004756A (ko) 항 정신질환제의 제조방법
KR860001110A (ko) 항균제 ⅱ의 제법
KR830007686A (ko) 세팔로 스포린 유도체의 제조방법
KR830006906A (ko) 시클로로프로판 카르복실레이트의 제조방법
KR850001724A (ko) 4-페닐-4-옥소-부텐-2-오인산유도체의 제조방법
KR830001952A (ko) 세펄옥심(Cefuroxim)의 제조방법
KR850004470A (ko) 유기 화합물의 제조방법
KR830005191A (ko) 푸란유도체의 제조방법
KR850004491A (ko) 아릴벤조티아졸린 유도체의 제조방법
KR900701746A (ko) 2-할로-4-알킬술포닐벤조산의 제조방법
KR850003407A (ko) 유기인산 에스테르 유도체의 제조방법
KR850005411A (ko) α-메틸-(6-펜옥시)-2- 피콜릴 사이클로프로판 카복실 레이트의 제조방법
KR840004720A (ko) 살충제 조성물 및 이의 제조방법
KR840005114A (ko) 아제티딘 술폰산의 제조방법
KR830001968A (ko) 할로 겐화제(Halogenating Reagents)의 제조방법
KR840007565A (ko) 시클로알케닐 유도체의 제조방법
KR850004471A (ko) 유기 화합물의 제조방법
KR840002848A (ko) 유기인산염의 제조방법
KR850006933A (ko) 설파모일-치환된 펜에틸아민 유도체의 제조방법
KR830005250A (ko) 빈크리스틴의 제조방법
KR860002473A (ko) 4-메틸-5-티오포름아미디노메틸이미다졸 디하이드로클로라이드의 제조방법
KR850004098A (ko) 부타놀 유도체의 제조방법
KR840004086A (ko) 1,3,5-트리아크릴일헥사하이드로-s-트리아진-유도체의 제조방법
KR880001636A (ko) 벤즈이미다졸 유도체의 제조 방법
KR830001254A (ko) 4-페닐-1,3-벤조디아제핀류의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19910419

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee